Teva Pharms Company Profile

✉ Email this page to a colleague

TEVA PHARMS has three hundred and eighteen approved drugs.

There are two US patents protecting TEVA PHARMS drugs. There are forty-four tentative approvals on TEVA PHARMS drugs.

There are seventeen patent family members on TEVA PHARMS drugs in twelve countries and nine hundred and sixteen supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	LURASIDONE HYDROCHLORIDE	lurasidone hydrochloride	TABLET;ORAL	208060-004	May 17, 2019		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Teva Pharms Usa	CLARAVIS	isotretinoin	CAPSULE;ORAL	076356-001	Apr 11, 2003	AB1	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Teva Pharms Usa	DEFERASIROX	deferasirox	GRANULE;ORAL	214180-003	Nov 19, 2021	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	7,820,203	⤷ Try a Trial
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	7,829,121	⤷ Try a Trial
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	6,054,430	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Injection	3.5 mg/vial	➤ Subscribe	2016-10-26
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-01-29
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	Extended-release Capsule	15 mg and 30 mg	➤ Subscribe	2008-08-11
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-02-26
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01

Patent Number	Expiration Date
⤷ Try a Trial	⤷ Try a Trial

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3150586	PA2020508,C3150586	Lithuania	⤷ Try a Trial	PRODUCT NAME: KOBICISTATAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS, DARUNAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS, YPAC DARUNAVIRO ETANOLATAS, IR EMTRICITABINAS, ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/17/1225 20170921
2371361	2019/055	Ireland	⤷ Try a Trial	PRODUCT NAME: PLERIXAFOR OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; NAT REGISTRATION NO/DATE: EU/1/09/537/001 20090804; FIRST REGISTRATION NO/DATE: EU/1/09/537/001 04/08/2009 (14/10/2020)
1411918	300537	Netherlands	⤷ Try a Trial	PRODUCT NAME: PLERIXAFOR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX; REGISTRATION NO/DATE: EU/1/09/537/001 20090804
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.